Prescribing trends in infectious keratitis: A survey of New Zealand ophthalmologists

Clinical and Experimental Ophthalmology

Volumn 31, Issue 6, 2003, Pages 496-504

  McAllum, Penny J ^a,b   McGhee, Charles N J ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Infectious; Keratitis; Ophthalmologists; Prescribing; Survey

Indexed keywords

ACICLOVIR; AMPHOTERICIN; ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CHLORHEXIDINE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOPLEGIC AGENT; DEXAMETHASONE; FLUOROMETHOLONE; GENTAMICIN; NATAMYCIN; NEOMYCIN; NEOSPORIN; NONSTEROID ANTIINFLAMMATORY AGENT; POLY(HEXAMETHYLENEBIGUANIDE); POLYMYXIN B; PREDNISOLONE ACETATE; PREDNISOLONE SODIUM PHOSPHATE; PROPAMIDINE; SULFACETAMIDE; TOBRAMYCIN;

ACANTHAMOEBA; ADENOVIRUS; ADULT; ARTICLE; BACTERIAL INFECTION; CLINICAL PRACTICE; CONJUNCTIVITIS; CORNEA DISEASE; DRUG PREFERENCE; EVIDENCE BASED MEDICINE; HEALTH SURVEY; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; KERATITIS; MEDICAL SPECIALIST; MYCOSIS; NEW ZEALAND; PRACTICE GUIDELINE; PRESCRIPTION; QUESTIONNAIRE; VIRUS INFECTION;

EID: 0346368395     PISSN: 14426404     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-9071.2003.00708.x     Document Type: Article

References (66)

1. Witcher JP, Srinivasan M. Corneal ulceration in the development world - A silent epidemic. Br J Ophthalmol 1997; 81: 622-3.
2. Wilhelmus KR, Gee L, Hauk WW et al. Herpetic eye disease study: A controlled trial of topical corticosteroids for herpes simplex stromal keratitis. Ophthalmology 1994; 101: 1883-96.
3. Herpetic Eye Disease Study Group. A controlled trial of oral acyclovir for the prevention of stromal keratitis or iritis in patients with herpes simplex virus epithelial keratitis. The Epithelial Keratitis Trial. Arch Ophthalmol 1997; 115: 703-12. [Erratum in Arch Ophthalmol 1997; 115: 1196.]
4. Herpetic Eye Disease Study Group. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. N Engl J Med 1998; 339: 300-6.
5. Radford CF, Lehmann OJ, Dart JK. Acanthamoeba keratitis: Multicentre survey in England 1992-1996. National Acanthamoeba Keratitis Study Group. Br J Ophthalmol 1998; 82: 1387-92.
6. Ellison AC, Newmark E, Kaufman HE. Chemotherapy of experimental keratomycosis. Am J Ophthalmol 1969; 68: 812-9.
7. Newmark E, Ellison AC, Kaufman HE. Pimaricin therapy of cephalosporium and fusarium keratitis. Am J Ophthalmol 1970; 69: 458-66.
8. Baum J, Barza M. Evolution of antibiotic treatment: 1970-2000. Cornea 2000; 19: 659-72.
9. The Ofloxacin Study Group. Ofloxacin monotherapy for the primary treatment of microbial keratitis: A double-masked, randomised, controlled trial with conventional dual therapy. Ophthalmology 1997; 104: 1902-9.
10. Gangopadhyay N, Daniell M, Weih L, Taylor HR. Fluoroquinolone and fortified antibiotics for treating bacterial corneal ulcers. Br J Ophthalmol 2000; 84: 378-84.
11. Hyndiuk RA, Eiferman MD, Caldwell DR et al. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group. Ophthalmology 1996; 103: 1854-63.
12. O'Brien TP, Maguire MG, Fink NE, Alfonso E, McDonnell P. Efficacy of ofloxacin versus cefazolin and tobramycin in the therapy for bacterial keratitis. Arch Ophthalmol 1995; 113: 1257-65.
13. Panda A, Ahuja R, Sastry SS. Comparison of topical 0.3% ofloxacin with fortified tobramycin plus kefazolin in the treatment of bacterial keratitis. Eye 1999; 13: 744-7.
14. Gudmundsson OG, Ormerod LD, Kenyon KR et al. Factors influencing predilection and outcome in bacterial keratitis. Cornea 1989; 8: 115-21.
15. Gebauer A, McGhee CN, Crawford GJ. Severe microbial keratitis in temperate and tropical Western Australia. Eye 1996; 10: 575-80.
16. Scott IU, Flynn HW Jr., Feuer W et al. Endophthalmitis associated with microbial keratitis. Ophthalmology 1996; 103: 1864-70.
17. Wilhelmus KR. Indecision about corticosteroids for bacterial keratitis. An evidence-based update. Ophthalmology 2002; 109: 835-44.
18. McLeod SD, DeBacker CM, Viana MA. Differential care of corneal ulcers in the community based on apparent severity. Ophthalmology 1996; 103: 479-84.
19. McDonnell PJ, Nobe J, Gauderman WJ, Lee P, Aiello A, Trousdale M. Community care of corneal ulcers. Am J Ophthalmol 1992; 114: 531-8.
20. Forster FK. Conrad Berens lecture. The management of infectious keratitis as we approach the 21st century. CLAO J 1998; 24: 175-80.
21. Morlet N, Gatus B, Coroneo M. Patterns of perioperative prophylaxis for cataract surgery: A survey of Australian ophthalmologists. Aust NZ J Ophthalmol 1998; 26: 5-12.
22. Elder M, Tarr K. The New Zealand cataract and refractive surgery survey 1997/1998. Clin Experiment Ophthalmol 2000; 28: 89-95.
23. Gordon JS. Adenoviruses and other nonherpetic viral diseases. In: Smolin G, Thoft RA, eds. The Cornea, 3rd edn. Boston: Little Brown, 1994; 215-27.
24. Romanowski EG, Roba LA, Wiley L et al. The effects of corticosteroids on adenoviral replication. Arch Ophthalmol 1996; 114: 581-5.
25. Ward JB, Siojo LG, Waller SG. A prospective, masked clinical trial of trfluridine, dexamethasone, and artificial tears in the treatment of epidemic keratoconjunctivitis. Cornea 1993; 12: 216-21.
26. Gordon YJ. The evolution of antiviral therapy for external ocular viral infections over twenty-five years. Cornea 2000; 19: 673-80.
27. Adams CP, Cohen EJ, Albrecht J, Laibson PR. Interferon treatment of adenoviral conjunctivitis. Am J Ophthalmol 1984; 98: 429-32.
28. Romanovski EG, Gordon YJ. Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model. Invest Ophthalmol Vis Sci 2000; 41: 460-3.
29. Romanovski EG, Araullo-Cruz T, Gordon YJ. Topical corticosteroids reverse the antiviral effect of topical cidofovir in the Ad5-inoculated New Zealand rabbit ocular model. Invest Ophthalmol Vis Sci 1997; 38: 253-7.
30. Laibson PR. Ocular adenoviral infections. Int Ophthalmol Clin 1984; 24: 49-64.
31. Kaufman HE, Rayfield RC. Viral conjunctivitis and keratitis. In: Kaufman HE, Barron BA, McDonald MB, Waltman SR, eds. The Cornea. New York: Churchill Livingstone, 1988; 325-7.
32. Dawson CR, Togni B. Herpes simplex eye infections: Clinical manifestations, pathogenesis and management. Surv Ophthalmol 1976; 21: 121-35.
33. Williams HP, Falcon MG, Jones BR. Corticosteroids in the management of herpetic eye disease. Trans Ophthalmol Soc UK 1977; 97: 341-4.
34. Jones BR. The clinical features of viral keratitis and a concept of their pathogenesis. Proc R Soc Med 1958; 52: 917-24.
35. Edgerton AE. Herpes zoster ophthalmicus. Arch Ophthalmol 1945; 93: 40-153.
36. Harding SP, Lipton JR, Wells JC. Natural history of herpes zoster ophthalmicus. Predictors of postherpetic neuralgia and ocular involvement. Br J Ophthalmol 1986; 71: 353-8.
37. Neoh C, Harding SP, Saunders D et al. Comparison of topical and oral acyclovir in early herpes zoster ophthalmicus. Eye 1994; 8: 688-91.
38. Marsh RJ, Cooper M. Double-masked trial of topical acyclovir with steroids in the treatment of herpes zoster ocular inflammation. Br J Ophthalmol 1991; 75: 542-6.
39. Akexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology 2000; 107: 1497-502.
40. Goldstein MH, Kowalski RP, Gordon YG. Emerging fluoroquinolone resistance in bacterial keratitis. A 5-year review. Ophthalmology 1999; 106: 1313-18.
41. Schaefer F, Bruttin O, Zografos L, Guex-Crosier Y. Bacterial keratitis: A prospective clinical and microbiological study. Br J Ophthalmol 2001: 85: 842-7.
42. Tuft SJ, Matheson M. In vitro resistance in bacterial keratitis in London. Br J Ophthalmol 2000; 84: 687-91.
43. Mallari PL, McCarty DJ, Daniell M, Taylor H. Increased incidence of corneal perforation after topical fluoroquinolone treatment for microbial keratitis. Am J Ophthalmol 2001; 131: 131-3.
44. Leibowitz HM, Ryan WJ, Kupferman A. Route of antibiotic administration in bacterial keratitis. Arch Ophthalmol 1981: 99: 1420-23.
45. Barza M. Treatment of bacterial infections of the eye. In: Remington JS, Swartz MN, eds. Current Clinical Topics in Infectious Diseases. New York: McGraw-Hill, 1980; 158-94.
46. Ormerod LD, Hertzmark E, Gomez DS, Stabiner RG, Schanzlin DJ, Smith RE. Epidemiology of microbial keratitis in southern California. A multivariate analysis. Ophthalmology 1987; 94: 1322-33.
47. Miedziak AI, Miller MR, Rapuano CJ, Laibson PR, Cohen EJ. Risk factors in microbial keratitis leading to penetrating keratoplasty. Ophthalmology 1999; 106: 1166-70.
48. Stern GA, Buttross M. Use of corticosteroids in combination with antimicrobial drugs in the treatment of infectious corneal disease. Ophthalmology 1991; 98: 847-53.
49. McGhee CN, Dean S, Danesh-Meyer H. Topically and periocular steroids: Assessing risks and benefits in ophthalmic practice. Drug Saf 2002; 25: 33-55.
50. Leibowitz HM, Kupferman A. Topically administered corticosteroids: Effect on antibiotic-treated bacterial keratitis. Arch Ophthalmol 1980; 98: 1287-90.
51. Engel LS, Callegan MC, Hobden JA, Reidy JJ, Hill JM, O'Callaghan RJ. Effectiveness of specific antibiotic/steroid combinations for therapy of experimental Pseudomonas aeruginosa keratitis. Curr Eye Res 1995; 14: 229-34.
52. Badenoch PR, Hay GJ, McDonald PJ, Coster DJ. A rat model of bacterial keratitis: Effect of antibiotic and corticosteroid. Arch Ophthalmol 1985; 103: 718-22.
53. Coster DJ, Badenoch PR. Host, microbial, and pharmacological factors affecting the outcome of suppurative keratitis. Br J Ophthalmol 1987; 71: 96-101.
54. Carmichael TR, Gelfand Y, Welsch NH. Topical steroids in the treatment of central and paracentral corneal ulcers. Br J Ophthalmol 1990; 74: 528-31.
55. Naginton J, Watson PG, Playfair TJ. Amoebic infection of the eye. Lancet 1974; 2: 1547-50.
56. Elder MJ, Kilvington S, Dart JK. A clinicopathological study of in vitro sensitivity testing and Acanthamoeba keratitis. Invest Ophthalmol Vis Sci 1994; 35: 1059-64.
57. Duguid IG, Dart JK, Morlet N et al. Outcome of Acanthamoeba keratitis treated with polyhexamethyl biguanide and propamidine. Ophthalmology 1997; 104: 1587-92.
58. Lim L, Coster DJ, Badenoch PR. Antimicrobial susceptibility of 19 Australian corneal isolates of Acanthamoeba. Clin Experiment Ophthalmol 2000; 28: 119-24.
59. Tay-Kearney ML, McGhee CN, Crawford GJ, Trown K. Acanthamoeba keratitis. A masquerade of presentation in six cases. Aust NZ J Ophthalmol 1993; 21: 237-45.
60. Horsburgh B, Hirst LW, Carey T, Whitby RM, Nimmo G, Stallard K. Steroid sensitive Acanthamoeba keratitis. Aust NZ J Ophthalmol 1991; 19: 349-50.
61. Moore MB, McCulley JP. Acanthamoeba keratitis associated with contact lenses: Six consecutive cases of successful management. Br J Ophthalmol 1989; 73: 271-5.
62. Rabinovich T, Weissman SS, Ostler HB, Sheppard JD, Teikari J. Acanthamoeba keratitis. Clinical signs and analysis of outcome. Rev Infect Dis 1991; 13 (SUPPL. 5): S427.
63. O'Day DM, Head WS. Advances in the management of keratomycosis and Acanthamoeba keratitis. Cornea 2000; 19: 681-6.
64. Johns KL, O'Day DM. Pharmacologic management of keratomycoses. Surv Ophthalmol 1988; 33: 178-88.
65. Foster CS. Fungal keratitis. Inf Dis Clin North Am 1992; 6: 851-7.
66. Wong T, Ormonde S, Gamble G, McGhee CNJ. Severe infective keratitis leading to hospital admission in New Zealand. Br J Ophthalmol 2003; 87: 1103-8.